Data Sheet

Product Name:	Rineterkib (hydrochloride)
Cat. No.:	CS-0147670
CAS No.:	1715025-34-5
Molecular Formula:	$C_{26}H_{28}BrClF_3N_5O_2$
Target:	ERK; Raf
Pathway:	MAPK/ERK Pathway; Stem Cell/Wnt
Solubility:	DMSO : 220 mg/mL (Need ultrasonic)



BIOLOGICAL ACTIVITY:

Rineterkib hydrochloride (compound B) is an orally available **ERK1** and **ERK2** inhibitor in the treatment of a proliferative disease characterized by activating mutations in the MAPK pathway. The activity is particularly related to the treatment of KRAS-mutant NSCLC, BRAF-mutant NSCLC, KRAS-mutant pancreatic cancer, KRAS-mutant colorectal cancer (CRC) and KRAS-mutant ovarian cancer. Rineterkib hydrochloride can also inhibit **RAF**[1][2]. **In Vivo:** ERK-IN-1 (compound B) (50, 75 mg/kg, p.o., qd/q2d, 27 days) treatment significantly reduces the tumor volume in the Calu-6 human NSCLC subcutaneous tumor xenograft model in mice[1].

References:

[1]. CAPONIGRO, et al. THERAPEUTIC COMBINATIONS COMPRISING A RAF INHIBITOR AND A ERK INHIBITOR. WO2018051306A1.

[2]. Song Y, et al. Targeting RAS-RAF-MEK-ERK signaling pathway in human cancer: current status in clinical trials. Genes & Diseases, 2022.

CAIndexNames:

Benzamide, 4-[3-amino-6-[(1S,3S,4S)-3-fluoro-4-hydroxycyclohexyl]-2-pyrazinyl]-N-[(1S)-1-(3-bromo-5-fluorophenyl)-2-(methylamino)ethyl]-2-fluoro-, hydrochloride (1:x)

SMILES:

O=C(N[C@@H](C1=CC(F)=CC(Br)=C1)CNC)C2=CC=C(C3=NC([C@@H]4C[C@H](F)[C@@H](O)CC4)=CN=C3N)C=C2F.[H]Cl.[x]

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 610-426-3128 Fax: 888-484-5008 E-mail: sales@ChemScene.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA